Neighborhood-Level Disadvantage Impacts on Patients with Fibrotic Interstitial Lung Disease
Gillian C. Goobie, Christopher J. Ryerson, Kerri A. Johannson, Erin Schikowski, Richard H. Zou, Nasreen Khalil, Veronica Marcoux, Deborah Assayag, Hélène Manganas, Jolene H. Fisher, Martin R. J. Kolb, Kevin F. Gibson, Daniel J. Kass, Yingze Zhang, Kathleen O. Lindell, S. Mehdi Nouraie
Abstract
Abstract Rationale Fibrotic interstitial lung disease (fILD) is a group of pathologic entities characterized by scarring of the lungs and high morbidity and mortality. Research investigating how socioeconomic and residential factors impact outcomes in patients with fILD is lacking. Objectives To determine the association between neighborhood-level disadvantage and presentation severity, disease progression, lung transplantation, and mortality in patients with fILD from the United States and Canada. Methods We performed a multicenter, international, prospective cohort study of 4,729 patients with fILD from one U.S. and eight Canadian ILD registry sites. Neighborhood-level disadvantage was measured by the area deprivation index in the United States and the Canadian Index of Multiple Deprivation in Canada. Measurements and Main Results In the U.S. but not in the Canadian cohort, patients with fILD living in neighborhoods with the greatest disadvantage (top quartile) experience the highest risk of mortality (hazard ratio = 1.51, P = 0.002), and in subgroups of patients with idiopathic pulmonary fibrosis, the top quartile of disadvantage experienced the lowest odds of lung transplantation (odds ratio = 0.46, P = 0.04). Greater disadvantage was associated with reduced baseline DL CO in both cohorts, but it was not associated with baseline FVC or FVC or DL CO decline in either cohort. Conclusions Patients with fILD who live in areas with greater neighborhood-level disadvantage in the United States experience higher mortality, and patients with idiopathic pulmonary fibrosis experience lower odds of lung transplantation. These disparities are not seen in Canadian patients, which may indicate differences in access to care between the United States and Canada.